The value of time-based outcomes in Alzheimer's research

Samuel Dickson, PhD, Pentara Corporation, Millcreek, UT, discusses recent publications on time savings in clinical studies, including work on nutritional studies and AD04, a novel therapeutic candidate for Alzheimer’s disease. Expressing the efficacy of an investigative agent as time saved compared to placebo (i.e., months saved with treatment) allows for easier comparison between different trials, as well as being a more intuitive way for patients to understand clinical meaningfulness. Dr Dickson highlights the development of a method for subject-level analysis that could be used as a secondary outcome in clinical research.This interview took place at the American Academy of Neurology (AAN) Annual Meeting 2024 in Denver, CO.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.